Netflix, Inc. (NFLX)’s Phenomenal Run

Netflix, Inc. (NASDAQ:NFLX) is in a phenomenal run, especially in the video streaming business at the back of increased expansion in the subads, of which Quartz Contributor, Jason Lynch, could not fail to point out in an interview on CNBC. The biggest question among many analysts is when the company will bulk to pressure and own a studio where they could hold stage time or retain resources instead of outsourcing.

Netflix, Inc. (NASDAQ:NFLX)

It is still not clear when the company will opt to buy its own studio considering the company is trying to have a good foothold of the space before making a final decision.

“It is unclear when that would happen, I think they still want to have a little more of a foothold but that is absolutely something down the line. Increasingly, we are seeing networks and studios trying to own their own content,” said Mr. Lynch.

The end game for Netflix, Inc. (NASDAQ:NFLX) remains uncertain as it continues to bolster its content in terms of programming, something that might transform into another Comcast Corporation (NASDAQ:CMCSA). There has been suggestions that the company could be headed to becoming a platform player as it tries to justify the confidence that investors have on it.

Netflix, Inc. (NASDAQ:NFLX) has already been successful in its foray of original programming better than earlier anticipated. The company continues to stock more series, and Mr. Lynch expects the company to make the transition to late night programming in two years’ time.

“Their early forays into original programming have been more successful than I think they would have even anticipated. So they are stocking the pipeline with even more series and then in two years, they are going to try and go into late night programming as well, and I think depending on how that goes, they could make an even bigger play down the line after that,” said Mr. Lynch.

Disclosure: none

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!